Concordance
Health Economics & MedTech Intelligence

Patients. Clinicians.
The system.

Your technology has to work for all three. We build the evidence that proves it.

Start a conversation → Read our insights
Patients Clinicians The System
Scroll

Whatever the innovation is, it needs to provide value, fulfil an unmet need for patients and clinicians and the system. It needs to be a win, win, win for all three — otherwise it's never going to work.

The Concordance philosophy
The questions behind the decisions
You need the health economics case before you commit
Every health technology decision depends on evidence. We help you build it.
01
"Is there a market for this?"
A properly evidenced addressable market that holds up in a board paper or investor pitch. Not a top-down estimate.
02
"What does NICE need to see?"
The regulatory pathway, the evidence gaps, and a plan to close them. Before you start generating evidence — not after.
03
"Where does it sit in the pathway?"
Current standard of care, placement options, adoption barriers. The clinical context that shapes your value proposition.
04
"Will the NHS adopt it?"
The economic case that commissioners need. Budget impact, workforce implications, and how your technology fits NHS priorities.
05
"Can we get funding?"
The health economics sections, NHS need narrative, and market context that strengthen your grant application.
06
"Should we invest?"
Independent assessment of the market opportunity, competitive landscape, and commercial viability. Evidence for investment decisions.
Services
Evidence that sharpens
your decisions
Health economics consulting for MedTech — diagnostics, AI, digital health, and medical devices. Every engagement is grounded in evidence.
Technology Positioning
Spin-outs & TTOs
Where does your technology sit in the clinical pathway? What's the addressable market? What evidence do you need? We build the health economics case that shapes your go-to-market strategy.
NICE Strategy & Evidence
NICE & HTA submissions
Pathway strategy, evidence gap analysis, study design guidance, and budget impact modelling. We help you understand what NICE needs to see — and build the case to show it.
Market Access & Reimbursement
Market entry & NHS adoption
Market sizing, competitive landscape, and the local reimbursement business case. For MedTech companies building an NHS adoption strategy from evidence, not assumptions.
Grant Support
NIHR & Innovate UK bids
We join your grant application as a named co-applicant, contributing the health economics and market context sections. We invest in your application alongside you.
Investor Due Diligence
PE / VC & acquirers
Independent market assessment for investors evaluating health technology opportunities. Market positioning, competitive landscape, regulatory pathway, and commercial viability — backed by evidence.
Annual Retainer
TTOs & innovation teams
Ongoing intelligence for organisations with a health technology portfolio. Market reads on any technology, deeper analysis when you need it, and regular briefings.
Insights
What we're seeing this week
We publish what we're seeing across the UK health technology landscape. The findings, not the methodology.
Diagnostic capacity

CT scanning volumes have grown 47% since 2019 — but the growth is concentrated in 12 ICBs

NHS imaging activity mapped by region. Where capacity is growing, where it's flat, and what that means for MedTech market entry.

14 February 2026
NICE adoption

18 months after NICE approval, 6 trusts still haven't prescribed

Trust-level variation in adoption speed. The adoption curve your market access strategy needs to account for.

10 February 2026
Cost variation

The same procedure costs between £28 and £312 depending on the trust

NHS reference cost variation across providers. Why national averages are misleading for your budget impact model.

7 February 2026
How we work
Rigour, not guesswork.
Evidence, not assumptions.
We don't start from scratch on every project. Our analysis draws on deep, continuously maintained expertise across the UK health technology landscape.
1
You brief us
Tell us about your technology, your clinical area, and the decisions you need to make.
2
We build the evidence base
Market landscape, regulatory context, clinical pathway, cost benchmarks, competitive positioning — assembled for your specific technology.
3
Expert analysis
A health economist reviews, contextualises, and interprets. We add strategic narrative and highlight what matters for your decision.
4
Actionable intelligence
A structured report with clear findings and evidence-backed recommendations for your board paper, grant, or investor pitch.
About
Health economics
with depth
Concordance was founded by a health economist who saw the same problem on every project: the evidence existed but nobody had assembled it properly. We built the expertise — and the approach — to do it right.

We work with tech transfer offices, MedTech companies, and investors. Our clients range from university spin-outs preparing for market entry to established companies building their UK health technology strategy.

Health Economics

Early economic modelling, value proposition development, NICE strategy, clinical pathway analysis, evidence gap assessment, and reimbursement business cases

Decision-maker Access

Direct experience interviewing clinicians, commissioners, and procurement leads across NHS trusts and ICBs

Tech Transfer Networks

Active relationships with university technology transfer offices and health innovation networks across the North of England

Deep Market Knowledge

We maintain a depth of understanding across the UK health technology landscape that means we're never starting from scratch

Ready to build the evidence your technology needs?

Whether you need a market landscape, a NICE strategy, or the health economics case for a grant — start with a conversation.

Start a conversation →